title: Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?
authors: Donat
authors: D
authors: Dürr
authors: Raffaele Daniele
authors: RD
authors: Siciliano
authors: Yvonne
authors: Y
authors: Hummel
authors: Alix
authors: A
authors: O'Meara
authors: Anita
authors: A
authors: Hirschi
authors: Roger
authors: R
authors: Burkhard
authors: Hanspeter
authors: H
authors: Honegger
mesh_terms: D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D017353:Gene Deletion; D006801:Humans; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide